公开(公告)号：US20150038484A1

公开(公告)日：2015-02-05

申请号：US14518165

申请日：2014-10-20

Applicant: Pfizer Inc.

Inventor： Samit Bhattacharya ,  Kimberly Cameron ,  Matthew Dowling ,  Dilinie Fernando ,  David Ebner ,  Kevin Filipski ,  Daniel Kung ,  Esther Lee ,  Aaron Smith ,  Meihua Tu

IPC: C07D413/12 ,  C07D405/10 ,  C07D403/12 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D401/10 ,  C07D209/42 ,  C07D405/12

CPC classification number: C07D413/12 ,  A61K31/404 ,  A61K31/416 ,  C07D209/42 ,  C07D231/56 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶（AMPK）的式（I）的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病，病症或障碍的方法。

公开(公告)号：US20130267493A1

公开(公告)日：2013-10-10

申请号：US13831588

申请日：2013-03-15

Applicant: PFIZER INC.

Inventor： Samit Bhattacharya ,  Kimberly Cameron ,  Matthew Dowling ,  Dilinie Fernando ,  David Ebner ,  Kevin Filipski ,  Daniel Kung ,  Esther Lee ,  Aaron Smith ,  Meihua Tu

IPC: C07D231/56 ,  C07D209/42 ,  C07D401/10 ,  C07D403/12 ,  C07D413/14 ,  C07D401/14 ,  C07D405/12

CPC classification number: C07D413/12 ,  A61K31/404 ,  A61K31/416 ,  C07D209/42 ,  C07D231/56 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶（AMPK）的式（I）的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病，病症或障碍的方法。

公开(公告)号：US11634410B2

公开(公告)日：2023-04-25

申请号：US17209780

申请日：2021-03-23

Applicant: Pfizer Inc.

Inventor： Matthew Dowling ,  Dilinie Fernando ,  Kentaro Futatsugi ,  Kim Huard ,  Thomas Victor Magee ,  Brian Raymer ,  Andre Shavnya ,  Aaron Smith ,  Benjamin Thuma ,  Andy Tsai ,  Meihua Tu

IPC: C07D403/14 ,  A61K31/403 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04

Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20210309644A1

公开(公告)日：2021-10-07

申请号：US17209780

申请日：2021-03-23

Applicant: Pfizer Inc.

Inventor： Matthew Dowling ,  Dilinie Fernando ,  Kentaro Futatsugi ,  Kim Huard ,  Thomas Victor Magee ,  Brian Raymer ,  Andre Shavnya ,  Aaron Smith ,  Benjamin Thuma ,  Andy Tsai ,  Meihua Tu

IPC: C07D403/14 ,  A61K31/403 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04

Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20190106412A1

公开(公告)日：2019-04-11

申请号：US16211283

申请日：2018-12-06

Applicant: Pfizer Inc.

Inventor： Matthew Dowling ,  Dilinie Fernando ,  Kentaro Futatsugi ,  Kim Huard ,  Thomas Victor Magee ,  Brian Raymer ,  Andre Shavnya ,  Aaron Smith ,  Benjamin Thuma ,  Andy Tsai ,  Meihua Tu

IPC: C07D403/14 ,  C07D403/04 ,  A61K31/403 ,  C07D401/04 ,  C07D401/14

Abstract: Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

公开(公告)号：US20150099882A1

公开(公告)日：2015-04-09

申请号：US14564263

申请日：2014-12-09

Applicant: Pfizer Inc.

Inventor： Mary Didiuk ,  Kevin J. Filipski ,  Angel Guzman-Perez ,  Esther C. Lee ,  Jeffrey A. Pfefferkorn ,  Benjamin Stevens ,  Meihua Tu

IPC: C07D241/44 ,  C07D217/22 ,  C07D215/38 ,  C07D239/84

CPC classification number: C07D239/84 ,  A61K31/517 ,  C07D215/38 ,  C07D217/22 ,  C07D239/94 ,  C07D241/44

Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, A1, A2, A3, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

公开(公告)号：US08889730B2

公开(公告)日：2014-11-18

申请号：US13831588

申请日：2013-03-15

Applicant: Pfizer Inc.

Inventor： Samit Bhattacharya ,  Kimberly Cameron ,  Matthew Dowling ,  Dilinie Fernando ,  David Ebner ,  Kevin Filipski ,  Daniel Kung ,  Esther Lee ,  Aaron Smith ,  Meihua Tu

IPC: A61K31/404 ,  C07D209/42 ,  A61P13/12 ,  A61P3/10 ,  C07D403/12 ,  C07D401/04 ,  A61K31/416 ,  C07D413/14 ,  C07D405/14 ,  C07D401/12 ,  C07D405/12 ,  C07D231/56 ,  C07D413/12 ,  C07D401/14 ,  C07D401/10

CPC classification number: C07D413/12 ,  A61K31/404 ,  A61K31/416 ,  C07D209/42 ,  C07D231/56 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D405/04 ,  C07D405/10 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

Abstract translation: 本发明涉及活化5'腺苷单磷酸活化蛋白激酶（AMPK）的式（I）的吲哚和吲唑化合物。 本发明还包括含有这些化合物的药物组合物和用于治疗或预防通过AMPK活化改善的疾病，病症或障碍的方法。